Free shipping on all orders over $ 500

Mivebresib

Cat. No. M5258

All AbMole products are for research use only, cannot be used for human consumption.

Mivebresib Structure
Synonym:

ABBV-075

Size Price Availability Quantity
2mg USD 90 In stock
5mg USD 115 In stock
10mg USD 180 In stock
Free Delivery on orders over USD 500 Bulk Inquiry?

Quality Control & Documentation
Biological Activity

In vitro: ABBV-075 exhibits robust single agent activity in cell viability assays across cancer cell lines derived from solid tumors, leukemia and lymphomas. It could disrupt cell cycle control leading to G1 arrest followed by senescence, inhibit oncogenesis drivers leading to apoptosis, and potentially target tumor microenvironment to provide additional therapeutic benefit.

In vivo: ABBV-075 has comparable or superior efficacies to standard of care agents in flank xenograft mouse models of non-small-cell and small cell lung cancers, pancreatic, breast, prostate, head & neck cancers, multiple myeloma, diffuse large B cell lymphoma and leukemia.

Chemical Information
Molecular Weight 459.47
Formula C22H19F2N3O4S
CAS Number 1445993-26-9
Solubility (25°C) 85 mg/mL in DMSO
Storage Powder          -20°C   3 years ;  4°C   2 years
In solvent       -80°C   6 months ;  -20°C   1 month
References

[1] Bui MH, et al. Cancer Res. Preclinical characterization of BET family bromodomain inhibitor ABBV-075 suggests combination therapeutic strategies.

[2] Faivre EJ, et al. Mol Cancer Res. Exploitation of Castration-Resistant Prostate Cancer Transcription Factor Dependencies by the Novel BET Inhibitor ABBV-075.

Related Epigenetic Reader Domain Products
RVX-208

Apabetalone (RVX-208) is a first-in-class, small molecule inhibitor of BET bromodomain with IC50 of 0.51 μM for BD2.

I-BET151

I-BET151 (GSK1210151A) is an inhibitor of the BET family with IC50 of 0.5 μM, 0.25 μM and 0.79 μM for BRD2, BRD3 and BRD4, respectively.

(+)-JQ1

(+)-JQ1 is a BET bromodomain inhibitor that acts on BRD4(2) with an IC50 of 33 nM and binds to all bromodomain domains in the BET family, but not to bromodomain domains outside the BET family. JQ1 down-regulates CD47 expression through a C-MYC-mediated pathway, and JQ1 down-regulates CD47 expression through a C-MYC-mediated pathway.

I-BET-762

I-BET-762 (GSK525762) is a selective small molecule BET inhibitor.

CPI-0610

CPI-0610 is a novel BET protein bromodomain inhibitor.

  Catalog
Abmole Inhibitor Catalog




Keywords: Mivebresib, ABBV-075 supplier, Epigenetic Reader Domain, inhibitors, activators

All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.



Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2026 AbMole BioScience. All Rights Reserved.